Scinai Immunotherapeutics Secures $2.61 Million to Expand CDMO Platform and Advance Pipeline

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has entered into a securities purchase agreement with institutional and accredited investors for the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants. The company also executed a separate warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions.

The capital raise is strategically timed to support Scinai's expansion of its contract development and manufacturing organization (CDMO) platform, advancement of customer programs, and continued investment in its immunotherapy pipeline. The company's CDMO subsidiary, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies, positioning Scinai to capitalize on growing demand for outsourced biopharmaceutical manufacturing.

Scinai's pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l., focusing on innovative immunology therapies. The additional funding will enable the company to advance these programs while scaling its CDMO operations to serve a broader client base. The warrant inducement agreement reflects ongoing investor confidence in Scinai's strategic direction.

For more details on the transaction, the full press release is available at https://ibn.fm/6Vw4O. Further updates on Scinai Immunotherapeutics can be found in the company's newsroom at https://ibn.fm/SCNI.